Abstract. The opioid growth factor (OGF), [Met 5 ]-enkephalin, and OGF receptor (OGFr) form an inhibitory axis regulating the growth of human pancreatic cancer. This study examined whether overexpression of OGFr decreases the growth of pancreatic cells in vitro. MIA PaCa-2 cells were transfected with OGFr cDNA, and six clonal lines were examined for protein expression and function. OGFr binding assays revealed a 2.3-to 5.6-fold increase in binding capacity from wild-type (WT) and empty vector (EV) controls; binding affinity was comparable in all groups. OGFr protein expression, as measured by immunohistochemistry and Western blotting, was enhanced in clonal cell lines compared to controls. Doubling times of OGFr clonal lines were 47-91% longer than in the WT/EV groups for all but one clonal line. DNA synthesis of cells overexpressing OGFr was diminished from the WT/EV groups by 28-52%. Addition of exogenous OGF further reduced (14-31%) the cell growth of clonal lines, and the effects of exogenous OGF were receptor-mediated. Exposure of cells overexpressing OGFr to naltrexone increased the cell number by up to 9.4-fold. OGF was identified as the only opioid peptide to depress cell replication in the transfected cell lines. Neutralization of endogenous OGF with antibodies to this peptide elevated the cell number in clonal cell lines. These data identify OGFr at the molecular level as integral to regulating the cell replication of human pancreatic cancer, and support treatment modalities that amplify OGFr in order to decrease the growth of these neoplasias.
Introduction
Pancreatic cancer is estimated to be 10th in the number of new cases of cancer in the United States and, with a 98% mortality rate, is the 4th leading cause of cancer-related deaths (1) . Globally, pancreatic cancer occurs in more than 168,000 individuals each year, and is the 9th leading cause of mortality from cancer (2) . The 5-year survival rate is 5% for patients with cancer of the pancreas (1) , and has changed only 2% in the last several decades, carrying one of the most dismal prognoses (3) . The problem of treating pancreatic cancer is compounded by a lack of early detection tools, resulting in 80% or more of patients having unresectable cancer at the time of initial diagnosis (4, 5) .
The opioid growth factor (OGF), chemically termed [Met 5 ]-enkephalin, is an endogenous opioid peptide that is an important regulator of the growth of human pancreatic cancer (6-18, Cheng F, et al, AACR 97th Ann Meet: abs. 2077, 2006) . OGF is a constitutively expressed native opioid that is autocrine produced and secreted, and interacts with the OGF receptor (OGFr) to inhibit the growth of pancreatic cancer cells in vitro and in tumor xenografts (7, 11, 12) . The action of OGF is tonic, stereospecific, reversible, non-cytotoxic and non-apoptotis inducing, not associated with differentiative processes, serum-and anchorage-independent, and occurs at physiologically relevant concentrations in a wide variety of pancreatic cancers including poorly-and well-differentiated human cell lines (7, 11, 12, (16) (17) (18) . The only opioid peptide, natural or synthetic, that influences the growth of pancreatic cancer is OGF (7, 11) . The action of this opioid in these neoplasias is targeted to DNA synthesis (15) and is directed toward the G 0 /G 1 interface of the cell cycle (15, Cheng F, et al, AACR 97th Ann Meet: abs. 2077, 2006), specifically the cyclin-dependent inhibitory kinase pathways (Cheng F, et al, AACR 97th Ann Meet: abs. 2077, 2006). Exogenous administration of OGF has a profound antitumor action on xenografts of pancreatic cancer that includes delaying tumor appearance and reducing tumor size (11) (12) (13) . The combination of biotherapy with OGF and chemotherapy with gemcitabine has proven to enhance antitumor effectiveness beyond either agent alone (11) .
The gene for human OGFr is at least 9 kb in length, consists of seven exons and six introns, and encodes a 677 amino acid protein that includes 7 imperfect repeats of 20 amino acids each and a bipartite nuclear localization signal (6, 14) . OGFr has an apparent mass of 62 kDa. The chromosomal location of the human OGFr is 20q13.3 (14) . Although OGFr has characteristics of a classical opioid receptor (recognizes opioids, naloxone reversibility, stereospecificity), there is no homology of OGFr with classical opioid receptors in terms of nucleotides or amino acids (6, 14) . Antisense experiments with OGFr and continuous blockade of opioid receptors by the potent opioid antagonist naltrexone (NTX) reveal that the OGF-OGFr axis is a tonically active inhibitory system targeted to cell replication and homeostasis, and is ligand-dependent for function (6, 14) . Immunoelectron microscopy and confocal microscopy studies have shown that OGFr is localized to the outer nuclear envelope, nucleus and perinuclear cytoplasm (19, 20) . Gene expression (13, 14) and protein expression (7, 12, 13) of OGFr, as well as binding activity (8, 12, 13) have been identified and characterized in pancreatic cancer cell lines revealing the autocrine nature of this growth regulatory axis.
In this study, we have asked whether the amplification of OGFr signaling in human pancreatic cancer may contribute to phenotypic changes, such as the loss of cell replication, which could be associated with malignant progression. To this end, we have used a tissue culture model of the MIA PaCa-2 cell line, derived from an undifferentiated epithelial carcinoma occurring in the body and tail of the pancreas in a 65-year old man (21) , and examined the effect of overexpressing OGFr on cell proliferation. The results show for the first time that overexpression of OGFr at the molecular level decreases cell replication and DNA synthesis of pancreatic cancer cells in tissue culture, indicating that OGFr is integral to the inhibitory action of OGF. The data also establish the fundamental principle that OGF and OGFr form an autocrine loop to regulate the growth of these neoplasias. Upregulation of OGFr may provide a novel target to inhibit pancreatic cancer suggesting that molecular and pharmacological strategies could be utilized for the treatment of this deadly neoplasia.
Materials and methods
Human tumor cell line. MIA PaCa-2 cells (21) were grown in monolayers at 37˚C in a humidified atmosphere with 5% CO 2 /95% air in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf heat inactivated serum, 1.2% sodium bicarbonate, and antibiotics (5,000 Units/ml penicillin, 5 mg/ml streptomycin, 10 mg/ml neomycin).
Transfection and clonal selection. MIA PaCa-2 cells were transfected with pcDNA3.1 + vector (empty vector, EV) or with the plasmid pcDNA3.1 + huOGFr in the presence of Lipofectamine 2000. Transfected cells were selected by growth in media containing G418 at 1 mg/ml; 12 clones were expanded and analyzed for binding capacity and growth. Based on the results of these experiments, six clones were maintained in G418 and characterized. For all experiments, wild-type (parental) cells (WT) and EV cell lines served as controls.
OGFr binding assays. Binding assays for OGFr were performed with procedures described earlier (8) . In brief, log-phase cells were harvested, and the nuclear fraction isolated through sucrose gradient centrifugation. Binding saturation isotherms were determined by specific binding of custom- Immunohistochemistry. To examine the presence of OGFr, log-phase cells from clonal lines, as well as WT and EV, were grown on 22-mm round coverglasses for 72 h. Immunohistochemistry was performed according to methods described previously (7) . Cells were fixed and permeabilized in 95% ethanol, followed by immersion in acetone (-20˚C), and stored at -20˚C for no more than 7 days before processing. Cells were incubated with ammonium sulfate purified antiOGFr-IgG (1:250) diluted in Sorenson's phosphate buffer with 1% normal goat serum in 0.1% Triton X-100 for 18 h at 4˚C. Coverglasses were washed and incubated with goat anti-rabbit IgG (1:100) conjugated to rhodamine and viewed with fluorescence microscopy. Antibodies to OGFr (I0029) were generated in the laboratory to a full-length rat OGFr fusion protein (22) . This antibody stained the 62-kDa protein of OGFr in a nuclear preparation, as well as proteolysis products of 32-, 30-, 17-, and 16-kDa of OGFr (unpublished observations), and recognized 50 ng of recombinant protein at a 1:100 dilution.
Protein isolation and Western blotting. Cell samples were isolated and nuclear preparations separated on 12% sodium dodecyl sulphate-polyacrylamide gel electrophoresis, and electrotransferred to nitrocellulose (22) . Western blotting was performed with primary antibodies to recombinant rat OGFr-GST fusion protein (IO407) (1:500), or with commercially available ß-actin (1:10,000) (BD Biosciences, Palo Alto, CA). Antibody IO407 detects human (and rat) OGFr at 50 ng at a 1:100 dilution, and recognizes the 62-kDa, as well as the 32-, 30-, 17-, and 16-kDa fragments, of OGFr. This antibody was purified over a glutathione-S-transferase Sepharose 4B column. Western blots were quantitated by densitometric measure of the 62-kDa band of OGFr. The optical density of ß-actin was used to standardize the protein load.
Cell proliferation. Transfected cell lines were seeded into 6-or 24-well plates, and cell number (trypan blue exclusion staining) was determined at 24-h intervals over a 3-to 4-day period. Growth curves were generated and doubling times were calculated by nonlinear curve fitting analyses (GraphPad Prism 4.0, San Diego, CA).
DNA labeling indexes.
To measure DNA synthesis, cells were plated onto 22-mm round coverglasses and grown in serum-containing media for 48 h prior to addition of 30 μM bromodeoxyuridine (BrdU) for 3 h. Cells were stained with anti-BrdU biotin conjugated primary antibody (1:20) (Molecular Probes/Invitrogen, Carlsbad, CA), followed by staining with goat anti-mouse HRP secondary antibody (1:1000) (Chemicon, Temecula, CA); BrdU-positive cells were counted from 10 random fields and the percent labeling index calculated. At least 1000 cells/cell line were counted.
Growth in the presence of OGF.
To determine whether an overexpression of OGFr changed the response of cells to the inhibitory pentapeptide OGF, transfected cell lines, along with WT and EV cells were grown in the presence of 5x10 -6 M OGF for 72 h. OGF or sterile water was added from 24 h after seeding (= 0 h); media and compounds were replaced daily. This OGF concentration was selected based on previous evidence demonstrating growth inhibition of pancreatic cancer cells (7) .
Opioid receptor mediated growth. To determine whether the transfected cell lines were expressing OGF receptors that responded to pharmacological characteristics defined previously (7), such as blockade by opioid antagonists, transfected cells lines, along with WT and EV cell lines were grown in the presence of 5x10 -5 M naloxone (Sigma-Aldrich, St. Louis, MO), a short-acting opioid antagonist, 5x10 -6 M OGF, both 5x10 -6 M OGF and 5x10 -5 M naloxone, or sterile water. Treatments began 24 h after seeding; media and compounds were replaced daily. Cells were counted 48 h after initiation of drug exposure. Effect of OGF antibody on cell proliferation. In order to determine if OGF played a role in basal regulation of growth in cells overexpressing OGFr, clonal cell lines and WT, were subjected to 1:200 dilutions of anti-OGF IgG (CO172) (21) and counted 72 h later. Media and antibody were replaced daily. Previous evidence (7) demonstrated no differences in cell number between non-immune IgG-treated and control cultures.
Statistical analysis. Cell numbers and/or absorbencies, as well as labeling indexes, were analyzed using analysis of variance (ANOVA) with subsequent comparisons made using Newman-Keuls tests. Data from binding assays were subjected to analysis by GraphPad Prism, and binding affinities and capacities were generated with this computer software.
Results

Establishment and characterization of the OGFr clones.
To study the effects of amplification of the OGF receptor on growth, MIA PaCa-2-derived clones that overexpressed OGFr were established. To generate these clones, MIA PaCa-2 cells were stably transfected with an OGFr expression vector, and 12 neomycin-resistant clones were characterized for OGF receptor binding and growth at 72 h after seeding (data not shown). Six clones (OGFr-1, -2, -4, -6, -7, and -8) with different levels of receptor expression as compared to the parental MIA PaCa-2 cell lines were expanded and further characterized (Figs. 1-7) . For all studies, comparisons were made to WT and/or EV cell lines.
Overexpression of OGFr upregulates receptor binding capacity.
To characterize further the MIA PaCa-2/OGFr clones, we determined the binding affinity (Kd) and binding capacity (Bmax) for each transfected cell line. Binding assays of radiolabeled [Met 5 ]-enkephalin for OGFr revealed specific and saturable binding in the nuclear enriched fraction of all cell lines. Binding affinities did not differ between WT, EV and clonal cell lines, with Kd values of 2.4±0.9 nM and 3.4±1.0 nM for the WT and EV groups, respectively, and a range of 3.2±1.2 to 8.6±2.1 nM for the mean Kd levels of clonal cells.
Binding capacity values for clonal cells, however, were markedly elevated compared to those of the WT (3.9±1.0) and EV (5.7±0.7) groups, with increases ranging from 2.3-to 5.6-fold recorded in cells with amplified OGFr (Fig. 1) . No differences in Bmax values between the WT and EV groups were noted.
OGFr protein is present and overexpressed in transfected cell lines. In order to confirm that OGFr protein is present and overexpressed at the structural level, immunohistochemical preparations of two selected clonal lines, OGFr-1 and OGFr-7, grown on coverslips for 72 h were performed using a polyclonal antibody to recombinant OGFr. A marked increase in immunofluorescence of these two clonal cell lines was observed relative to WT ( Fig. 2A) and EV cells (data not shown). For all cell lines, OGFr was visible in the cytoplasm and the nucleus. Cells processed with secondary antibody only showed no staining (data not shown). Photodensitometric measurements (Fig. 2B ) revealed that exposure times for clonal lines OGFr-1 and OGFr-7 were decreased by 43% and 38%, respectively, compared to that of the WT group; exposure times of the WT and EV cells were similar. Thus, the decrease in photodensitometric values for OGFr in the OGFr-1 and OGFr-7 cell lines reflects the increased fluorescence from overexpression of OGFr protein.
Western blot analysis of OGFr in nuclear-enriched preparations indicated that the 62-kDa band was present in all preparations (Fig. 2C) . Densitometric analysis of films revealed that the 62-kDa band of OGFr protein, standarized for loading with actin, was elevated 2.0-, 2.4-and 2.5-fold in clonal cell lines OGFr-1, -4, and -7, respectively, relative to WT cells (Fig. 2D) ; no differences were observed between the WT and EV cells.
Overexpression of OGFr downregulates cell proliferation.
The functional repercussions of amplified OGFr in MIA PaCa-2 were determined by evaluation of cell growth over a 96-h period. In general, differences between cell lines overexpressing OGFr and the WT and EV cultures were detected at 48, 72, and/or 96 h after seeding (see Fig. 3A for a representative growth curve). Calculation of doubling times based on multiple growth curves/cell line revealed that in all but one of the clonal cell lines (OGFr-2), cells amplifying OGFr had a longer doubling time compared to the WT and EV groups that ranged from no changes in OGFr-2 to a 91% increase in the OGFr-4 group (Fig. 3B) . No differences in doubling times were observed between the WT and EV groups (~22 h).
DNA labeling indexes are decreased in cells with an abundance of OGFr.
To assess one mechanism of the changes in growth observed in cell lines overexpressing OGFr, labeling indexes of clonal pancreatic cell lines subjected to BrdU were evaluated. In comparison to the labeling index of WT cells (37.2±2.9%), 5 of 6 clonal cell lines overexpressing OGFr had 28-52% fewer cells incorporating BrdU (Fig. 4) . The WT and EV groups were similar concerning the number of labeled cells (~38%).
Addition of exogenous OGF to cell cultures overexpressing OGFr heightens the decreases in cell number.
In earlier studies (7, 11, 15) , addition of exogenous OGF to pancreatic cancer cultures depressed cell growth, leading to the prediction that exogenous OGF introduced to cells overexpressing OGFr will have an exaggerated inhibitory response. In fact, the number of cells in cultures OGFr-1, -4, -6, and -7 was reduced by 13-38% compared to that in the WT cultures (Fig. 5A) ; no differences between the WT and EV groups were detected. The addition of exogenous OGF to these clonal cell lines depressed growth even further, reducing cell numbers by 14-31% compared to their respective basal levels at 72 h (Fig. 5B) . Summation of the percent basal growth inhibition calculated from cell number at 72 h and data on the percent inhibition of cell lines after exposure to OGF for 72 h, showed a total growth inhibition of the clonal cell lines that was 1.6-to 4.0-fold greater than that for the EV group, which had a 17% reduction (Fig. 5C ).
The effect of exogenous OGF on the growth of cells transfected with OGFr is opioid receptor-mediated.
To establish whether the growth inhibitory effects of OGF on cells overexpressing OGFr was receptor-mediated, cells were grown in the presence of the short-acting opioid antagonist, naloxone, to temporarily block opioid receptors (Fig. 6 ). Cell lines with amplified OGFr (OGFr-7) and treated with 5x10 -6 M OGF had a 14% decrease in cell number at 72 h compared to cells receiving sterile water, whereas the EV cells receiving OGF decreased 9% in cell number compared to their respective basal levels. Addition of 10 -5 M naloxone to cultures exposed to 5x10 -6 M OGF, revealed that the EV and OGFr-7 cultures had cell numbers comparable to their respective basal levels. Moreover, cultures of EV and OGFr-7 cells exposed to 10
-5 M naloxone alone demonstrated no growth inhibition.
Naltrexone increases cell number in cells overexpressing
OGFr. To understand the effects of opioid receptor blockade with a potent and long-acting opioid receptor antagonist on cells with an abundance of OGFr, NTX was added to cultures of clonal cell lines (Fig. 7) . Clonal lines subjected to two concentrations of NTX exhibited an increased cell number compared to basal levels in OGFr-1, OGFr-4, and EV cultures. However, the magnitude of change was greater in clonal cell lines OGFr-1 and OGFr-4 than in the EV cells, and this was especially noticeable with 5x10 -5 M NTX. Thus, EV, OGFr-1, and OGFr-4 cell lines increased 45%, 44%, and 5.2-fold, respectively, when subjected to NTX at a concentration of 10 -5 M, and increased 32%, 2.3-fold, and 9.4-fold, respectively, when exposed to 5x10 -5 M NTX.
OGF is the specific opioid peptide that depresses growth in cells overexpressing
OGFr. Although opioid peptides other than OGF have not been found to influence the growth of human pancreatic cancer cells in culture (7), the effects of these other opioid peptides on the growth of cells overexpressing OGFr required elucidation. OGFr-1 and OGFr-7 cells were treated daily with 10 -6 M concentrations of a variety of natural and synthetic opioid ligands; in some cases, these ligands were specific for μ, ‰, or κ opioid receptors. Morphine, DAMGO, DPDPE (d-Pen,d-Pen-enkephalin), dynorphin 1-13, endomorphin-1, endomorphin-2, U69,593, and ß-endorphin were not found to alter the growth of either clonal cell line (data not shown).
Increased proliferation of transfected cells with OGFr exposed
to an OGF antibody. In order to examine the repercussion of depleting endogenous OGF in cultures of cells overexpressing OGFr, WT, OGFr-1, and OGFr-7 cell lines were seeded in 96-well plates and allowed 24 h before addition of the OGF antibody CO172; media and antibody were replaced daily. At 72 h, OGFr-1 and OGFr-7 cells exposed to OGF antibody had 50% and 37%, respectively, more cells than transfected cell lines receiving sterile vehicle. WT cells subjected to OGF antibody had a 46% increase in cell number.
Discussion
This study provides major insights into the molecular mechanisms of the OGF-OGFr axis and is the first to report the successful stable transfection of the OGF receptor, with resulting translation of OGFr protein, in a cancer cell line. Receptor binding assays of clonal cell lines using radiolabeled OGF ligand showed 2.3-to 5.6-fold more receptors in these cells than in WT or EV cell lines. As expected, the molecular and cellular nature of the amplified OGFr protein was not changed with respect to binding affinity, permitting an understanding of the biological effects solely from increasing the number of OGF receptors. Qualitative and quantitative immunohistochemical staining of OGFr in clonal cell lines revealed a substantial increase of this receptor protein in these cells compared to WT and EV cell lines, however the location and distribution of OGFr in clonal cells did not differ from that in WT or EV cells. Protein expression of OGFr in clonal lines was increased from WT and EV groups as measured by Western blotting. It should be noted that WT and EV cell lines were similar in all experiments (e.g. protein levels, receptor binding), arguing that the vector itself was not a confounding influence. Moreover, the selection and characterization of six clonal lines insured that the outcome of the transfection was not an isolated observation in one clonal cell line. This report is the original observation revealing that targeted overexpression of the OGF receptor has marked repercussions on growth and DNA synthesis of human pancreatic cancer cells. All clonal lines had decreased DNA synthesis by up to 50% compared to the parental line or EV. Moreover, doubling times of all but one MIA PaCa-2 cell line transfected with OGFr cDNA were increased by more than 50% compared to WT and EV cells. Four of the clonal cell lines exhibited 13-38% decreases in cell number relative to either the parental cell line or that of the EV, indicating that the overexpression of OGF receptors altered the basal level of cellular duplication. These results are consistent with previous reports that the OGF-OGFr axis is targeted to cyclin- ). This would suggest that the equilibrium in cell replication is disturbed by the addition of OGF receptors, with the net result being an exaggeration in growth inhibition and diminishment in cell number. The sensitivity of cellular events to the addition of OGF receptors was also observed when exogenous OGF was added to the cultures and the clonal cell lines had even further reductions (by 14-31% compared to respective basal levels) in growth. Thus, despite the increase in OGF there are a sufficient number of OGF receptors to respond to even higher levels of peptide. Moreover, the magnitude of expression of OGFr is rate limiting for OGFr signaling, and is an absolute requirement for activation of the OGF pathway. In addition, the effects of exogenous OGF on cells with amplified receptors was receptormediated, as demonstrated by the neutralization of OGF action with naloxone. Finally, the total growth inhibition of clonal cell lines with respect to the summation of basal levels and addition of exogenous OGF, decreased cell number by 1.6-to 3-fold compared to that of the WT and EV cells exposed to OGF. These data indicate that introduction of OGFr cDNA into these neoplastic cells has dramatic effects on growth by activating the OGF-OGFr inhibitory axis. Conversely, it might be conjectured that underexpression of OGFr could confer a growth advantage to the progression of pancreatic cancer. Future studies that attenuate OGFr in pancreatic cancer are required to examine this hypothesis.
Examination of the data revealed that receptor number alone could not be used as a predictor of growth. For example, one clonal cell line that had 4.4-fold more receptors than parental cells displayed a 13% decrease in basal growth, whereas another clonal cell line that had a 3.4-fold increase in binding capacity exhibited a 38% decrease in cell number. Thus, although the integrity of the OGF receptors appeared to be intact based on binding experiments and protein levels, other factors (e.g. nucleocytoplasmic transport) appeared to be at work in determining function. Such observations of differences in transfection studies between translation and function have been reported previously (23, 24) . However placing this clonal variation aside, it should be emphasized that all of the cell lines with increased OGF receptors had marked alterations in cell replication.
In previous reports, OGF has been identified as the opioid peptide that binds to OGFr and activates a response signal in pancreatic cancer (7) . This peptide has been found to be produced and secreted by a variety of cells so that the elements regulating cell proliferation are dependent on the cell itself (6, 7) . In the present study, a test of this ligand-dependent axis was made in clonal cell lines overexpressing OGFr by subjecting these cells in culture to an antibody to OGF. As in the WT and EV cells exposed to the antibody to OGF, clonal cells with enhanced expression of OGFr increased in number compared to the levels of those not treated with the antibody. Thus, cells overexpressing OGFr reacted in the predicted manner to depletion of OGF from the culture media. These data are consistent with the postulate that the OGF-OGFr axis is in an autocrine loop and integral to the regulation of pancreatic cancer, with disturbances of peptide or receptor markedly altering homeostatic equilibrium and bringing about changes in growth.
The finding that OGFr is activated by OGF raises the question of whether the changes seen in growth by clonal lines were due, wholly or in part, to increases in OGF levels because of a compensatory mechanism related to the abundance of the receptor. A number of observations argue that this is not the case. First, if OGF increased in proportion to the abundance of OGF receptors, then one would predict that clonal lines with the greatest number of receptors would have the highest levels of opioids and the largest decreases in growth. However, as mentioned earlier, no correlation was found between factors such as the number of OGF receptors and growth effects. Second, previous experiments with opioid receptor blockade using opioid antagonists have shown an upregulation of opioid peptides, so that an abundance of opioid agonists would be expected to result in a downregulation, rather than an upregulation, of opioid levels. Therefore, although there is a need to examine OGF levels in cultures of clonal cell lines with amplification of OGFr, it would not appear that changes in OGF values as a result of OGFr overexpression are responsible for the observed growth alterations.
The present observations on the effects of additional OGF receptors in pancreatic cancer cells with respect to growth complement those in previous studies regarding changing OGF-OGFr interactions. Antisense technology which attenuates OGFr levels has revealed marked increases in the number of human neuroblastoma and rat intestinal epithelial cells compared to control levels (6, 14) , whereas blockade of OGFOGFr interactions with opioid antagonists such as naltrexone also elevates cell number, including that of pancreatic cells such as MIA PaCa-2 (7, 15) . These findings are consistent with the present results showing that overexpression of OGFr decreases the number of pancreatic cancer cells, and that exposure to NTX increases cell replication. Our data are also consistant with reports that transient transfection of OGFr cDNA into rat corneal epithelial cells in vivo using a gene gun depresses DNA synthesis (25) and wound healing (26) . We now show that stable transfections of OGFr cDNA can markedly suppress cell growth in a cancer cell under in vitro conditions. Whether these pancreatic cancer cells with an overexpression of OGFr also have delays in growth in vivo remains to be determined.
Clinically, the OGF-OGFr axis has been detected using receptor binding, immunohistochemistry, and Western blotting in biopsy and surgical specimens of human pancreatic cancer (8, 14) . Studies on the transplantation of human pancreatic cancer cells into nude mice have revealed that the OGF-OGFr axis is functional in vivo (11, 12) . Given that pancreatic cancer is the 9th leading cause of mortality in the world (2) , and that the survival rate for this neoplasia has not improved substantially in decades (1), strategies for treatment of this lethal cancer are needed. In the present study, we found that introduction of additional OGFr into pancreatic cancer has a dramatic effect on cell number. Therefore, gene therapy to reinstate OGFr with functional effects could provide a useful treatment for inhibiting tumor progression.
